Iluvien Implants Yield 12-month Benefit for Diabetic Macular Edema

Source: Medscape

Wednesday, February 22, 2017 | Medical Studies , Alimera Sciences


The anatomical and visual benefits of intravitreal fluocinolone acetonide implants in patients with chronic diabetic macular edema (DME) persist up to 12 months, a small study suggests. The efficacy and safety of fluocinolone acetonide implants (Iluvien) have been demonstrated in clinical trials but not in long-term real-world experience.

Open in New Window

Comments

You must be logged in to leave a comment.